Tebapivat by Agios Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.

Dec 31, 2024 - 06:00

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase I for Sickle Cell Disease.

Read the original article

Tags:

Previous Article

UT Health San Antonio Study Reveals Smartphone App Can Lower Opioid Use and

LXE-408 by Novartis for Chagas Disease (American Trypanosomiasis): Likelihood of...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: What the Covid-19 pandemic can teach us about drug patents

STAT+: What the Covid-19 pandemic can teach us about dr...

May 3, 2023

CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar

CymaBay maps out regulatory filing for primary biliary ...

Sep 21, 2023

Half of people worldwide at risk of developing mental health condition by age 75, per new study

Half of people worldwide at risk of developing mental h...

Aug 9, 2023